Introduction
Colorectal cancer remains a leading cause of mortality worldwide despite the well-characterized molecular events in the adenoma-to-carcinoma sequence (1) . Screening for CRC has been shown to reduce disease incidence and cancer mortality. Several screening methods are available, but none is ideal (2) .
The diagnostic stage determines survival but, unfortunately, many colorectal cancers are recognized after regional or distant metastasis has occurred (3) . Treatment options for the advanced stages of the disease are limited, but favorable chances are greatly increased in early disease, therefore, the most effective means of reducing colorectal cancer mortality is early detection. Current modalities for screening, which include fecal occult blood testing (FOBT), flexible sigmoidoscopy and colonoscopy, have been available for decades, but their
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use in the general population is far below the recommended levels. Colonoscopy is currently the most effective means of detecting colonic lesions. Patient discomfort and distaste for this procedure, costs, lack of physician training and equipment, are some of the obstacles to the wide dissemination of this screening test (2) . A simple blood test capable of early CRC detection and/or of monitoring CRC progression would mean significant reduction of costs and higher compliance from the CRC patient population, often reluctant to undergo colonoscopy. A bloodbased assay for the detection of circulating tumour cells identified by a selected panel of CRC specific mRNAs potentially represents a more accessible screening tool.
Modest improvements in patient survival from CRC have been achieved in the last few decades, and the overall 5-year survival rate remains at 40-45%. Surgical resection is the treatment of choice for CRC; however, nearly one-half of all patients who undergo a potentially curative resection will relapse because of undetected micrometastasis. This suggests that tumour cell dissemination occurs early in the disease process and emphasizes the need for easily accessible diagnostic methods with sufficient sensitivity and specificity (3) . The spontaneous circulation of tumour cells and/or tumour microemboli is the hallmark of the 'invasive and metastatic behaviour' of a subset of cancer cells. Their detection is expected to provide a powerful tool for cancer prognosis, diagnosis of minimal residual disease, assessment of tumour sensitivity to anticancer drugs, and personalization of anticancer therapy (4, 5) . A highly sensitive and specific identification of circulating tumour cells (CTC) and circulating tumour microemboli (CTM) could also be helpful for an early diagnosis of invasive cancers (6) .
From simulation models, it has been estimated that from each gram of tumour tissue around 1x10 6 tumour cells can be introduced daily into the bloodstream (7) . Solid tumours as small as 2 mm in diameter typically display active angiogenesis and are hence capable of releasing tumour cells into peripheral blood. In the earlier stages of disease, disseminated cells are not capable of forming metastases, but they may represent a source for cancer detection.
Epithelial cancer cells have very low survival rates into the circulation (8) . The fate of CTC includes a rapid phase of intravascular cancer cell disappearance, which is completed in <5 min and accounts for 85% of the circulating cancer cells (9, 10) .
This process has been related to 'anoikis' (apoptosis induced by the disruption of cell attachment and cell-matrix interactions processes). Many cancer cell types with increased metastatic potential are resistant to anoikis compared to their parental cells, and the tumour phenotype appears to be related to the expression of apoptosis inhibitors (9) . Based on evidence from animal studies, where tumour local invasion and intravasation are bypassed (because of technical difficulties) and tumour cells are directly introduced into the systemic circulation, it has been established that around 1/40 CTC give rise to micrometastases and only ~0.01% proliferates into macrometastasis (11) .
The number of tumour circulating cells may be very small; therefore, methods for detecting them need to be both sensitive and specific. RT-PCR is potentially a very sensitive technique that has been proven to detect minute amounts of specific mRNA species in the total amount of RNA. The success of this technique depends on the availability of a specific target, consistently distinguishing tumour cells from blood cells (12) .
Detection of circulating neoplastic cells in patients with CRC has hitherto been carried out using a small number of different RNA targets. Carcinoembryonic antigen (CEA) has been chosen as a target (12) (13) (14) (15) (16) since this cell surface molecule is constitutively expressed in the colonic epithelial tissue (12) and its expression is maintained in almost all colorectal carcinomas. Cytokeratins, a multigene family of proteins with differentiation-associated patterns of expression, have also been used to characterize neoplastic cells of epithelial origin in the peripheral blood (15, (17) (18) (19) (20) (21) . Epidermal growth factor receptor (EGFR) mRNA is an alleged specific marker of circulating epithelial cells (16, 22, 23) . Furthermore, Guanyl cyclase C (24), tumour splice variants of CD44 (25) , MUC1 and MUC2 (26) , matrilysin MMP7 and HeLa metastatic gene (HLM) (22) , Apolipoprotein A-I (27) , and MAGE (28) mRNAs have also been tested for the same purpose. However, in most of these studies the expression of the targeted mRNAs was also detected in the peripheral blood of control subjects, free of neoplastic disease. In other cases, low sensitivity has hampered the usefulness of the assay.
At present, therefore, no available assay allows for early molecular detection of CRC in clinical practice. The aim of our research was to identify new potential molecular markers of CRC cell detection in peripheral blood, using bioinformatics investigation tools. This approach was used to recognize an optimal subset of genes suitable for early and highly specific detection of circulating CRC cells by a simple, qualitative reverse transcriptase-polymerase chain reaction assay. Our results include the identification of new colon-specific genes.
Patients and methods
Patients. The study was approved by the ethics committee of Sant'Orsola-Malpighi General Hospital and complied with the Ethical Principles for Medical Research Involving Human Subjects of the Helsinki Declaration. Written, informed consent was obtained from all patients and healthy control before study entry. Eight unrelated patients with a histologically confirmed diagnosis of CRC and 9 healthy subjects were enrolled in the study. Peripheral blood sample were obtained from each patient and control. The main clinical data of the patients are summarized in Table I .
RNA sources.
A peripheral blood sample (5 ml) was obtained from each patient just before surgery. To reduce contamination of samples with skin epithelial cells from the needle stick, the first ml of blood was discarded. The whole blood was then drawn into an EDTA tube and RNA extracted within one hour of being drawn, as described below. In addition, peripheral blood samples from 9 healthy donors were collected and processed with the same method and used as control. Total RNA samples from CRC commercially obtained from Stratagene were used as an additional positive control.
Identification of potential molecular markers.
The identification of potential molecular markers for CRC cell detection was performed using a systemic approach by bioinformatics tools. SAGE DGED (http://cgap.nci.nih.gov/SAGE/) is an original computer approach for statistical analysis of differential gene expression patterns that identifies those genes expressed at significantly different levels (as defined by the user) in two pools of human cDNA libraries, based on SAGE (29) tag analysis. The algorithm takes into account the differences in sample size between Pools A and B, which can be large. The user selects a value for statistical significance (P-value) and a value for the difference in the level of expression (F-value) between the two pools. The results are based on the sequence odds ratio and measures of significance.
For this study two pools were created and analyzed, the first encompassing all cDNA libraries from colon tissue (normal as well as neoplastic and tumour associated), while the second included all cDNA libraries from white blood cells (normal as well as neoplastic and tumour associated), to highlight colon-specific genes, having ideally a level of expression equal to zero in the blood. The formula for the sequence odds ratio is: (Seqs A / Total Sequences in A)/ (Seqs B / Total Sequences in B), where A and B are the selected pools. We selected genes with more than 100 tags for colon libraries (Table II) .
RNA extraction. Blood samples were lysed within one hour of being drawn, diluting 1 ml of whole blood with 1 ml of DEPC water and adding 6 ml TRIzol Ls (Invitrogen). Then, 6 ml of lysed cells was added to the sample suspension, passing the suspension several times through a pipette.
The lysate was stored at -80˚C until RNA extraction. Extraction was performed according to the manufacturer's instructions. Total RNA extracted from 1 ml of peripheral blood was then subjected to standard ethanol precipitation, and the pellet was resuspended in sterile bidistilled water to a final concentration of up to 0.5 μg/μl, 1 U of RNAase enzyme was added, and then the sample was stored at -20˚C.
Reverse transcription-polymerase chain reaction (RT-PCR)
amplification. Total RNA from peripheral blood (~1 μg) or total RNA from commercial human colon was reverse transcribed into a final volume of 25 μl in the presence of 500 μM each of deoxynucleotide triphosphate (dNTP), 200 units reverse transcriptase (Murine Moloney leukemia virus) with Table I . The main clinical data of the patients. - -- --------------------------------------------------------------------------------------------------- companion buffer 1X (Promega, Madison, WI, USA) and oligo dT-15 5 μM. The incubation was performed at 42˚C for 1 h, followed by denaturation at 95˚C for 5 min. The primers for amplification were designed using the software Amplify, following standard criteria. Primer sequences are given in Table III . Primers were designed on different exons for each gene. PCR experiments were performed in a final volume of 25 μl, containing 10 μl RT mix, 1 U Taq polymerase (Takara, Shiga, Japan) with companion reagents (0.2 mM each dNTP, 1.5 mM MgCl 2 , 1X PCR buffer), and 0.4 mM of each primer. An initial denaturation step of 2 min at 94˚C was followed by amplification for 40 cycles (30 sec at 94˚C, 30 sec at 61˚C, 30 sec at 72˚C) and final extension for 7 min at 72˚C. All the RT-PCR products obtained were analysed by gel electrophoresis following standard methods (30): ethidium bromide incorporation in the gel (0.5 μg/ml final concentration), and photography by GelDoc 2000 system (Bio-Rad, Hercules, CA).
Each potential marker was tested by RT-PCR on 8 CRC patients, 9 healthy controls, and on 1 μg of RNA from CRC tissue from Strategene. In some cases, genes expressed in at least three normal subjects were not further analyzed, as they were obviously unsuitable as cancer markers. BM2 was used as positive control of RT-PCR product.
Results

Identification of potential molecular markers.
Using a systematic bioinformatics approach we were able to identify a first series of potential molecular markers for CTC detection. In particular, DGED analysis produced a list of genes that are differentially expressed (P<0.001) between a pool of 4 colon libraries and a pool of 14 blood libraries. This powerful tool was able to compare 195,160 tags from colon tissue to 946,843 tags from blood. We selected the best genes significantly expressed in the colon (with a fraction of tags present in the colon pool >100) and virtually not expressed in the blood (with a fraction of tags present in the blood pool equal to 0.00000), as shown in Table II . The genes selected were: LOC644844, FABP1, CEACAM5, MUC13, GUCA2A, ABP1, and SLC26A3.
Reverse transcription-polymerase chain reaction (RT-PCR) amplification.
RT-PCR products of the expected size of 6 of the 7 candidates markers were obtained from all 9 healthy samples and 5 of 7 were also obtained from the CRC samples. The genes were tested in healthy controls (Fig. 1 ) and in patients (Fig. 2) , and a clear cut-off between the two groups Table III . The primers used. was not detected. ABP1, CEACAM5, MUC13, GUCA2A, FABP1 and SLC26A3 were first tested on 9 normal subjects.
-------------------------------------------------Primer Sequences 5'→3' -------------------------------------------------
CEACAM5 L CACCCTGGATGTCCTCTATGGGCCG CEACAM5 R TGGCCCCAGCTGAGAGACCAGGA ABP1 L CCGTGGTCTTTGAGCAGTTT ABP1 R GCCACACGATCACAGTGTCT SLC26A3 L CTGGCGCCTCTACAAAAGTC SLC26A3 R ACACTAGCTGCCAGGCCTAA MUC13 L TCCCTGGGAAGATTTCAGTG MUC13 R AACCATTGAGGCAGTCATCC FABP1 L GCAGAGCCAGGAAAACTTTG FABP1 R TCTCCCCTGTCATTGTCTCC GUCA2A L GGGGTCACCGTGCAGGATGGAA GUCA2A R GTCCCTGCTGCGGAGGGGAGG B2M L GTGGGATCGAGACATGTAAGCAGC B2M R CTCCTAGAGCTACCTGTGGAGCAA ------------------------------------------------- L,
-------------------------------------------------
ABP1 was found to be clearly positive in 7 of the 9 control subjects while SLC26A3 was positive in 4.
CEACAM5, MUC13, GUCA2A appeared to be favorable candidate colon markers because they were almost absent in the normal subjects tested and were highly expressed in CRC tissue from Stratagene. However, no positivity for these markers was found in the patient blood samples (Fig. 2) .
FABP1 was also negative in normal blood, but its expression level in CRC tissue from Stratagene was too low to qualify as an effective marker, and it was also negative in the blood samples of CRC patients. We were not able to amplify LOC644844 cDNA, as its expression value was too low also in the positive control (data not shown). Therefore, this gene was removed from the study.
Discussion
Early detection is one of the most effective means of reducing CRC related mortality. According to the World Health Organization, the criteria for developing and/or applying a screening test for cancer include acceptability, practicability, high specificity and high sensitivity (31) .
The RT-PCR assay for detection of circulating tumour cells in peripheral blood potentially represents a sensitive and accessible screening tool, able to detect minute amounts of specific RNA species amid the total amount of RNA. However, this technique has been, to date, unsuccessfully employed, due to the difficulty in identifying specific molecular markers able to distinguish CRC cells from blood cells.
The candidate genes, identified without any a priori knowledge in the present study as markers of colonic circulating cells in the peripheral blood of patients with different stages CRC, have already been reported to be specific for intestinal expression. For example, the MUC13 is a member of genes encoding complex mucosal glycoproteins that can be highly expressed by adenocarcinomas. These glycoproteins have diagnostic, therapeutic, and biological significance. MUC13 encodes a cell surface membraneanchored mucin, expressed in the normal gastrointestinal tract and trachea as well as in colorectal, esophageal, gastric, pancreatic, and lung cancers. MUC13 protein expression was determined immunohisto-chemically in 99 sporadic CRC, by assessing the proportion of tumour cells stained, the staining intensity, and their localization. In normal colon, intense apical membrane and variable cytoplasmic MUC13 staining was present in both goblet and columnar cells, with strongest reactivity in the upper crypts and surface epithelium. MUC13 was expressed abundantly in all colorectal cancers, with the highest expression seen in poorly differentiated tumours (32) . GUCA2A is a bioactive intestinal peptide involved in the cystic fibrosis transmembrane conductance regulator (CFTR)-regulated electrolyte/water secretion. Interestingly, a previous study, using microarray analysis, found SLC26A3 to be downregulated in colon cancer tissue in comparison to normal tissue. The authors suggested that SLC26A3 might function as a tumour suppressor gene in CRC (33) .
We expected that, within our highly selected set of colon tissue specific genes, we could identify genes with a cut-off able to distinguish control subjects and patients with colon cancer at different stages. Surprisingly, 2 of the 6 genes studied (ABP1 and SLC26A3) were expressed in the vast majority of CRC patients considered, but also in most of the control subjects. Some of the genes analysed had previously been considered epithelial-specific. This finding confirms that the task of identifying a useful mRNA cancer marker is not trivial, and that the extreme sensitivity of RT-PCR is able to detect minimal amounts of mRNA expressed in a non-tissuespecific manner.
The concept that any gene may be expressed in any cell type, albeit at a low level, is known as 'illegitimate transcription'. It has been speculated that gene expression in the absence of specific transcription factors may be very low, but not equal to zero. Expression of DNA that is part of condensed chromatin may be impossible under most conditions, but these inactive states of DNA may change when replication is taking place. Although these expression levels are very low (it is estimated that one transcript of any gene is present in any collection of 500-1,000 cells), this amount is however detectable by RT-PCR (33, 34) . These results are similar to those previously obtained by our group (35) , for another set of candidate markers, identified by expressed sequence tag (EST) based approach, rather than by SAGE DGED.
However, the finding that the expression of MUC13 and FABP1 is detectable in human colon tissues but not in blood samples rules out the hypothesis that illegitimate transcription is a universal phenomenon, which would exclude all possibility of finding a useful mRNA marker (36) .
Interestingly, we were able to identify by DGED 2 candidates, CEACAM5 and FABP1, that were already described as CTC associated genes by gene expression profiling, and specifically up-regulated in the metastatic CRC patient's blood (37) . The same authors selected SLC2A10 as CTC associate gene, belonging to the same family of our candidate, SLC26A3, which seems to be a useful marker because it is localized in the mucosa of the lower intestinal tract, particularly in the apical membrane of columnar epithelium.
Our research is the first one testing ABP1, GUCA2A and MUC13 as blood marker in CRC patients. MUC13 seemed to be promising candidate because is known as strong differentiation marker for gastrointestinal mucosa. Differently from other authors, that used MUC1 and MUC2 as blood markers, our member of the mucin family seems to be more specific for colon rather than epithelial tissue (32) .
Alternative approaches to circumvent the need for a clear cut-off between positive and negative samples could be quantitative RT-PCR, or the use of a combination of several markers to achieve statistical significance. The consistency of results obtained by quantitative RT-PCR among different laboratories is often questioned, and it is known that this test is commonly difficult to optimize and interpret. Assays incorporating a combination of multiple markers would be a reasonable approach, although we feel that the existence of a major locus functioning as a master marker could be a crucial feature for the applicability of the test.
In conclusion, to date the search for a useful mRNA marker for detection of colon cancer cells in peripheral blood has involved repeated trials often limited to the same small set of genes. By employing a systematic, open approach such as the one described here, there is a concrete possibility to find few genes or at least a single major locus suitable for diagnostic RT-PCR, based on a total ~30,000 genes available in the human genome. DGED is a powerful tool to identify differentially expressed candidate genes.
The test of a marker is best conducted in patients with clearly diagnosed colon cancer, and is possibly the basis for the development of a further prospective study targeting early diagnosis in population screening. However, among the gene set tested in this study, there was no clear cut-off between healthy subjects and patients with colon cancer. Further investigations, aimed at selecting the best candidate markers using large-scale approaches and at validating them with a simple blood test by RT-PCR, are required.
